Search Results

ABIONYX Pharma acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an acute myocardial infarction, did not meet its primary efficacy endpoint of MACE reduction at 90 days.

CSL’s AEGIS-II trial and cell and gene therapy expansion highlight the significant global expansion within the company over the past five years.

For the third year, CSL Plasma will provide influenza vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month.